Latest ebit for 3118.TWO: $68M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Sep 30, 2026
Trailing 12 months ending Sep 30, 2026
Level Biotechnology (3118.TWO) currently reports a EBIT of $68M as of September 2026. That compares with $99M in the prior-year period — down 31.3% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Level Biotechnology's EBIT history and peer comparisons.
Level Biotechnology's EBIT decreased from $99M to $68M — a 31.3% year-over-year decrease (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Level Biotechnology's EBIT of $68M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Level Biotechnology reported $68M in EBIT as of September 2026. That compares with $99M in the prior-year period — down 31.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $68M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Level Biotechnology, and consider following 3118.TWO for alerts when major investors trade the stock.